These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19165200)

  • 1. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.
    Descamps G; Gomez-Bougie P; Venot C; Moreau P; Bataille R; Amiot M
    Br J Cancer; 2009 Jan; 100(2):366-9. PubMed ID: 19165200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
    Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.
    Moreau P; Cavallo F; Leleu X; Hulin C; Amiot M; Descamps G; Facon T; Boccadoro M; Mignard D; Harousseau JL
    Leukemia; 2011 May; 25(5):872-4. PubMed ID: 21321571
    [No Abstract]   [Full Text] [Related]  

  • 5. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642.
    Descamps G; Wuillème-Toumi S; Trichet V; Venot C; Debussche L; Hercend T; Collette M; Robillard N; Bataille R; Amiot M
    J Immunol; 2006 Sep; 177(6):4218-23. PubMed ID: 16951388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
    Wu KD; Zhou L; Burtrum D; Ludwig DL; Moore MA
    Cancer Immunol Immunother; 2007 Mar; 56(3):343-57. PubMed ID: 16832681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
    Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
    Mannava S; Zhuang D; Nair JR; Bansal R; Wawrzyniak JA; Zucker SN; Fink EE; Moparthy KC; Hu Q; Liu S; Boise LH; Lee KP; Nikiforov MA
    Blood; 2012 Feb; 119(6):1450-8. PubMed ID: 22144178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
    J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
    Ri M; Iida S; Ishida T; Ito A; Yano H; Inagaki A; Ding J; Kusumoto S; Komatsu H; Utsunomiya A; Ueda R
    Cancer Sci; 2009 Feb; 100(2):341-8. PubMed ID: 19068089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
    Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
    Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
    Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW
    Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
    Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
    Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
    Gu H; Chen X; Gao G; Dong H
    Mol Cancer Ther; 2008 Aug; 7(8):2298-307. PubMed ID: 18723477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
    Yang M; Huang J; Pan HZ; Jin J
    Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
    Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
    Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.